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Dear Home Secretary, 
 
Re: Consideration of the use of foil as an intervention to support recovery. 
 
Thank you for your letter of 22nd November 2012. The ACMD is pleased to write with 
further advice, as requested, about whether the provision of foil assists individuals in 
achieving recovery.  
 
The ACMD fully supports your goal of getting individuals off drugs. The ACMD 
considers the legal provision of foil to support initial transition as part of a recovery 
journey; helping someone on their first steps towards initial recovery goals of moving 
away from the negative health impacts of injecting towards engaging with treatment 
services.  
 
The available evidence shows that the provision of foil at treatment centres does 
increase the number of individuals who engage with the services1. In turn, 
engagement with treatment services increases the likelihood of an individual’s 
recovery. The ACMD’s view is that foil, as an intervention, can support an individual 
in their first steps into treatment and towards recovery i.e. getting them off drugs. 
 
Recovery from injecting drug use (particularly heroin injecting) has been shown to be 
one of the most difficult journeys to make, not least because of the significant 
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collateral damage that injecting heroin often incurs. Evidence indicates that over half 
of heroin injectors suffer premature deaths related to heroin injecting2 and the Health 
Protection Agency’s annual publication ‘Shooting Up’3 tracks the significant rates of 
blood borne viruses and infections among injecting drug users.  
It is important to recognise that foil provision is an established practice at many 
needle exchanges. Also, guidelines provided by the National Treatment Agency4 and 
National Institute for Health and Clinical Excellence5 promote ‘reverse transition’ (the 
switch from injecting to smoking heroin). 
 
It is central to the ACMD’s view that an individual should have the opportunity to 
break the cycle of drug taking, particularly when it involves injecting. Consideration 
should therefore be given to providing foil in the structured and formal context of an 
individual’s treatment and recovery plan. 
 
The current statutory prohibition of foil provision prevents those delivering treatment 
from providing it legally as part of a tailored intervention. There may be merit in 
considering ways of devolving the provision of foil to healthcare professionals and 
allowing for local assessment of where its provision is appropriate.  
 
Both I and my colleagues would welcome discussing with you further.  
 
 
Yours sincerely, 
 
 
 
 
Professor Les Iversen CBE FRS 
 
 
CC: Parliamentary Under Secretary of State for Health, Anna Soubry 
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